• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Edgewise

Edgewise Therapeutics

A Movement in Muscle

  • Clinical Trials
  • Careers
  • Investors & News
  • Menu
    • Disease Areas
    • Muscular Dystrophy
    • Hypertrophic Cardiomyopathy

    Learn more about how our science is driving a new understanding of muscle and its potential to transform human health.

    Explore Muscle

    • Science & Pipeline
    • Pipeline
    • Sevasemten
    • EDG-7500
    • Clinical Trials
    • Posters & Presentations

    All of us at Edgewise are committed to developing new medicines for people facing serious muscle diseases with unmet medical needs.

    Explore our Science

    • Patients & Families
    • Support for Becker
    • Support for Duchenne
    • Support for HCM
    • Patient Stories

    We honor the experience of individuals and families living with and facing the challenges of serious muscle disease.

    Read their Stories

    • Company
    • Leadership Team
    • Careers
    • Contact Us

    Our vision is to improve the lives of patients and families suffering from serious muscle diseases by building the world’s leading muscle-focused company.

    Learn More

    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Governance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts
HomeScience & PipelineEDG-7500

EDG-7500

Targeting HCM and other serious diseases of cardiac diastolic dysfunction

We are developing EDG-7500, a selective cardiac sarcomere modulator, with the aim to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM).

Hypertrophic Cardiomyopathy

Two major forms of HCM include obstructive (oHCM) and non-obstructive (nHCM), each leading to impaired cardiac performance. In oHCM, as the left ventricle (LV) contracts (systole) to eject oxygenated blood from the heart into systemic circulation, the mitral valve makes physical contact with the hypertrophied septal wall. This contact underlies the basis of the obstructed ejection of blood through the LV outflow tract (LVOT) creating a pressure difference, or gradient (LVOT-G) between the LV cavity and systemic circulation. In nHCM, the hypertrophy is more symmetrically distributed in the LV walls, therefore the patient does not develop LVOT obstruction nor pressure gradient. However due to LV hypertrophy and stiffness, LV relaxation is impaired and LV filling with blood (diastole) is significantly reduced.

Abnormalities in a HCM Heart Lead to Impaired Cardiac Performance

HCM is a Disease of the Sarcomere

In HCM, the disease causes an increase in acto-myosin head engagement, making the heart hyperdynamic and relaxation impaired.


Normal contraction

Healthy sarcomere

Excessive contraction
and impaired relaxation

In HCM, too many ‘motors’ engaged during systole and diastole

About EDG-7500

Targeting the sarcomere

EDG-7500 is a novel oral, selective cardiac sarcomere modulator for the treatment of HCM and other serious diseases of cardiac diastolic dysfunction.

Learn more about HCM

Potential to address both obstructive and non-obstructive HCM

In preclinical data in models of both obstructive and non-obstructive HCM, EDG-7500 has been shown to improve cardiac relaxation and filling, without significant impairment of systolic performance.

View our EDG-7500 presentations

Designed to address unmet needs in HCM

Preclinical data support EDG-7500 has the potential for significant efficacy, measured by gradient response, without sacrificing safety concerns, measured in minimal changes in ejection fraction. EDG-7500 is currently in clinical trials in oHCM and nHCM.

Learn more about EDG-7500 clinical trials

EDG-7500 is an investigational therapy that has not been approved for use in hypertrophic cardiomyopathy by any regulatory agency, as its safety and effectiveness have not been established for the treatment of this disease.

Footer

Edgewise Therapeutics
  • Disease Areas
  • Science & Pipeline
  • Patients & Families
  • Company
  • Investors & News

Deep knowledge of integrated 
muscle physiology

Learn more about how our science is driving a new understanding of muscle and its potential to transform human health.

Explore our Science

2025 © Copyright. Edgewise Therapeutics. All Rights Reserved.

  • Privacy Policy
  • Terms of Use
Facebook X, formally Twitter LinkedIn Instagram YouTube
logo
  • Disease Areas
    • Muscular Dystrophy
    • Hypertrophic Cardiomyopathy
  • Science & Pipeline
    • Pipeline
    • Sevasemten
    • EDG-7500
    • Clinical Trials
    • Posters & Presentations
  • Patients & Families
    • Support for Becker
    • Support for Duchenne
    • Support for HCM
    • Patient Stories
  • Company
    • Leadership Team
    • Careers
    • Contact Us
  • Investors & Media
    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Goverance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts